Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
65.30    0.40 (0.62%)
Bid:
65.10
Ask:
65.30
Spread: 0.20 (0.307%)
Market Cap: £576.88m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Further re Scrip Dividend

14 Sep 2022 16:33

RNS Number : 4936Z
IP Group PLC
14 September 2022
 

FOR RELEASE ON

14 September 2022

 

IP Group plc - Further re Scrip Dividend

 

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, announces that, further to the announcements dated 03 August 2022, 18 August 2022 and 13 September 2022 in connection with the Interim Scrip Dividend, the Group has received valid elections from shareholders resulting in a requirement to issue 154,718 new ordinary shares of 2p each ("New Shares"). 

 

An application has been made for the New Shares to be issued in connection with the Scrip Dividend to be admitted to the premium segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange respectively.

 

Admission of the New Shares is expected to be effective on 20 September 2022. Following admission and in accordance with the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Group will have 1,063,188,005 Ordinary Shares in issue and 28,607,622 Ordinary Shares in Treasury.

 

The total number of Ordinary Shares with voting rights following the issue of the New Shares will be 1,034,580,383 Ordinary Shares. This figure may be used by shareholders in the Group as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Group under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

David Baynes, Chief Financial and Operating OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7967 312125

 

Notes for editors

 

About IP Group

 

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURGPUGWBUPPGAC
Date   Source Headline
4th Apr 20256:08 pmRNSTransaction in Own Shares
3rd Apr 20255:55 pmRNSTransaction in Own Shares
2nd Apr 20256:10 pmRNSTransaction in Own Shares
1st Apr 20255:25 pmRNSTransaction in Own Shares
31st Mar 20255:33 pmRNSTotal Voting Rights
31st Mar 20255:31 pmRNSTransaction in Own Shares
31st Mar 20257:00 amRNSTransaction in Own Shares
28th Mar 20253:42 pmRNSHolding(s) in Company
27th Mar 20256:07 pmRNSTransaction in Own Shares
26th Mar 20255:34 pmRNSTransaction in Own Shares
26th Mar 20254:38 pmRNSHolding(s) in Company
26th Mar 202511:53 amRNSHolding(s) in Company
26th Mar 202511:13 amRNSHolding(s) in Company
26th Mar 20257:00 amRNSTransaction in Own Shares
25th Mar 20257:00 amRNS2024 Annual Results
25th Mar 20257:00 amRNSTransaction in Own Shares
24th Mar 20257:00 amRNSTransaction in Own Shares
21st Mar 20257:00 amRNSTransaction in Own Shares
20th Mar 20257:00 amRNSTransaction in Own Shares
19th Mar 20257:00 amRNSTransaction in Own Shares
18th Mar 20256:11 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSNotice of Results
18th Mar 20257:00 amRNSTransaction in Own Shares
14th Mar 20256:11 pmRNSTransaction in Own Shares
14th Mar 20257:00 amRNSTransaction in Own Shares
12th Mar 20255:15 pmRNSTransaction in Own Shares
12th Mar 20257:00 amRNSTransaction in Own Shares
11th Mar 20257:48 amRNSPortfolio company Hinge Health files for IPO
10th Mar 20255:53 pmRNSTransaction in Own Shares
7th Mar 20255:16 pmRNSTransaction in Own Shares
7th Mar 20253:31 pmRNSHolding(s) in Company
6th Mar 20255:55 pmRNSTransaction in Own Shares
6th Mar 20257:00 amRNSTransaction in Own Shares
4th Mar 20256:26 pmRNSTransaction in Own Shares
3rd Mar 20255:51 pmRNSTransaction in Own Shares
3rd Mar 20257:00 amRNSTotal Voting Rights
28th Feb 20255:16 pmRNSTransaction in Own Shares
28th Feb 20257:00 amRNSTransaction in Own Shares
27th Feb 20257:00 amRNSTransaction in Own Shares
25th Feb 20256:09 pmRNSTransaction in Own Shares
24th Feb 20255:17 pmRNSTransaction in Own Shares
24th Feb 20257:00 amRNSTransaction in Own Shares
21st Feb 20257:00 amRNSTransaction in Own Shares
19th Feb 20256:14 pmRNSTransaction in Own Shares
19th Feb 20257:00 amRNSTransaction in Own Shares
18th Feb 20257:00 amRNSTransaction in Own Shares
17th Feb 20257:00 amRNSIstesso update on P2b study of leramistat in RA
17th Feb 20257:00 amRNSTransaction in Own Shares
14th Feb 20257:00 amRNSTransaction in Own Shares
12th Feb 20255:36 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.